Ingenza is pleased to announce it has successfully applied for EU H2020 SME Instrument funding of €50,000 for Phase 1 of its innovative SYNBIOMAN project, allowing the company to forge ahead with the development of this novel synthetic biology-driven biomanufacturing…
Ingenza is using its proprietary inABLE® technology to help develop a robust, versatile platform for the production of cyclic peptides for therapeutic use. This work is part of a collaboration with researchers at the University of Aberdeen and the University…
Ingenza Ltd, a world leader in the application of industrial biotechnology and synthetic biology, is pleased to announce that it is collaborating with global healthcare company GlaxoSmithKline (GSK) on an innovative research project. A vital part of any collaboration is…